Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2009-06-29
2011-12-13
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S139100, C424S158100
Reexamination Certificate
active
08075886
ABSTRACT:
Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
REFERENCES:
patent: 5194375 (1993-03-01), Park et al.
patent: 6555520 (2003-04-01), Sims et al.
patent: 6844170 (2005-01-01), Moore et al.
patent: 6861227 (2005-03-01), Ruben et al.
patent: 6890734 (2005-05-01), Reche-Gallardo et al.
patent: 6955895 (2005-10-01), Pandey et al.
patent: 6982320 (2006-01-01), Moore et al.
patent: 7071308 (2006-07-01), Reche-Gallardo et al.
patent: 7304144 (2007-12-01), Sims et al.
patent: 7405058 (2008-07-01), Sims et al.
patent: 7504105 (2009-03-01), Ruben et al.
patent: 2002/0068323 (2002-06-01), Saris et al.
patent: 2003/0186875 (2003-10-01), De Waal Malefyt et al.
patent: 2004/0091970 (2004-05-01), Bazan et al.
patent: 2007/0048781 (2007-07-01), Bazan et al.
patent: 1129190 (2007-05-01), None
patent: WO 99/47538 (1999-09-01), None
patent: WO 00/17362 (2000-03-01), None
patent: WO 00/29581 (2000-05-01), None
patent: WO 01/12672 (2001-02-01), None
patent: WO 02/00724 (2002-01-01), None
patent: WO 02/068588 (2002-09-01), None
Chuntharapai et al (1997), Methods in Enzymology, vol. 288, pp. 15-27.
Akashi, et al., “Lymphoid precursors”,Curr Opin Immunol, 12(2)144-150, Apr. 2000.
Aspinall, et al., “Thymic atrophy in the mouse is a sluble problem of the thymic environment,” Vaccine, 18(16):1629-1637, Feb. 25, 2000.
Beverly, et al., “Is immune senescence reversible?”, Vaccine, 18(16):1721-1724, Feb. 25, 2000.
Bolin, et al., “HNMP-1: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury”, J. Neurosci, 17(14):5493-5502, Jul. 15, 1997.
Fehniger, et al., “Differential cytokine and chemokine gene expression by human NK cells following activation with II-15 in combination with IL-12; implications for the innate immune response”, J. Immunol, 162(8):4511-4520, Apr. 15, 1999.
Kadowaki, et al., “Natural interferon alpha/beta-producing cells link innate and adaptive immunity,” J. Exp. Med., 192(2):219-226, Jul. 17, 2000.
Katz, et al., “Streptavidin-binding and -dimerizing ligands discovered by phage display, topochemistry, and structure-based design” Biomol Eng., 16(1-4):57-65, Dec. 31, 1999.
Kelleher, et al., “Functions of tetramer-stained HIV-specific CD4(+) and CD8(+) T cells”, Curr. Opin. Immunol., 12(4):370-374, Aug. 2000.
Kitmura, “New experimental approaches in retrovirus-mediated expression screening”, Int. J. Hematol., 67(4): 351-359, Jun. 1998.
Koppelman, et al., “Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of moncytes by affecting arrival and recycling”, Immunity, 7(6):861-871, Dec. 1997.
Levin, et al., “Thymic stromal lymphopoeitin (TSLP): A cytokine that promotes the development of IgM+B cells in vitro and signals via a novel mechanism”, FASEB Journal, vol. 13, No. 4, Part 1, Mar. 12, 1999, p. A322 XP008014578, Annual Meeting of the Professional Research Scientists for Experimental Biology 99, Washington DC, USA, Apr. 17-21, 1999 ISSN 0892-6638, the whole document.
Ogg, et al., “HLA-peptide tetrameric complexes”, Curr. Opin. Immunol., 10(4):393-396, Aug. 1998.
Pandey, et al., “Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin”, Nature Immunology, vol. 1, No. 1, pp. 59-64, Jul. 2000.
Park, et al., “Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor”, J. Exp. Med., 192(5):659-670, Sep. 4, 2000.
Puel, et al., “Mutations in the gene for the IL-7 receptor result in T(−)B(+)NK(+) severe combined immunodeficiency disease”, Curr. Opin. Immunol., 12(4):468-73, Aug. 2000.
Sims, et al., “Molecular cloning and biological characterization of a novel murine lymphoid growth factor”, J. Exp. Med., 192(5):671-680, Sep. 4, 2000.
Stoddart, et. al., “The role of the preBCR, the interleukin-7 receptor, and homotypic interactions during B-cell development”, Immunol. Rev. 175:47-58, Jun. 2000.
Waldmann, et al., “T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma”, Ann. Oncol. 11 Suppl. 1:101-106, 2000.
U.S. Appl. No. 12/174,871, Jul. 17, 2008, Bazan et al.
U.S. Appl. No. 12/174,889, Jul. 17, 2008, Bazan et al.
Soumelis, V., et al., Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP, Nature Immunology, vol. 3, No. 7, pp. 673-680, 2002.
Hammad, H., et al., “Th2polarization by Der p 1-pulsed monocyte-derived dendritic cells is due to the allergic status of the donors”, Blood, vol. 98, No. 4, pp. 1135-1141 (2001).
Mosmann, T.R., “Th1 and Th2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties”, Ann. Rev. Immunol., vol. 7, pp. 145-173 (1989).
Novak, N., “Dendritic cells in allergy”, Allergy, vol. 54, pp. 792-803 (1999).
Reche, P., “Human Thymic Stromal Lymphopoietin Preferentially Stimulates Myeloid Cells”, The Journal of Immunology, vol. 167, pp. 336-343 (2001).
Li, Y., “Thymic Stromal Lymphopoietin Promotes Lung Inflammation Through Activation of Dendritic Cells”, Journal of Asthma, vol. 47, p. 117-123 (2010).
Bazan J. Fernando
de Waal Malefyt Rene
Kastelein Robert A.
Liu Yong-Jun
Reche-Gallardo Pedro A.
Mertz Prema
Schering Corp
LandOfFree
Method of treatment using an anti-IL-B50 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment using an anti-IL-B50 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using an anti-IL-B50 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315569